Wire Stories
AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer�s Patients
SEONGNAM, South Korea–(BUSINESS WIRE)–AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, the topline results from its phase 2 study...